LSm3 inhibitors represent a specialized class of chemical compounds that target the LSm3 protein, a core component of the LSm protein family involved in RNA processing. The LSm (Like-Sm) proteins, comprising seven members, are known for their role in forming stable complexes that interact with RNA, particularly in the context of RNA splicing, degradation, and stabilization. LSm3, along with its counterparts, forms a heptameric ring structure that associates with small nuclear RNAs (snRNAs), playing a pivotal role in the assembly of the spliceosome, a cellular machinery critical for pre-mRNA splicing. Inhibition of LSm3, therefore, has a profound impact on RNA metabolism, affecting processes like the maturation of snRNAs, stabilization of uridine-rich small nuclear RNAs (U-snRNAs), and involvement in the degradation of mRNA through the exosome complex. The disruption of LSm3's normal function through specific inhibitors can lead to alterations in RNA processing dynamics at a fundamental cellular level.
Chemically, LSm3 inhibitors are often designed to interact with the binding sites on the LSm3 protein or the interface regions where LSm3 associates with other LSm proteins in the complex. This interaction is highly specific due to the precise nature of the LSm3 protein's role in RNA processing, often requiring inhibitors to possess molecular features that can effectively target these protein-protein or protein-RNA interactions. Structurally, LSm3 inhibitors may mimic or disrupt key contacts within the LSm ring complex, leading to its destabilization or altered conformation. By affecting the integrity of the LSm3-containing complexes, these inhibitors can provide valuable insights into the mechanistic aspects of RNA biology and the roles of LSm proteins in regulating RNA stability and turnover. The study of LSm3 inhibitors thus provides an essential tool for understanding the molecular basis of RNA metabolism and the regulatory networks that govern cellular RNA processing pathways.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D intercalates into DNA and could prevent the transcription of the LSm3 gene by blocking the advancement of RNA polymerase along the DNA template. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide disrupts eukaryotic protein synthesis by inhibiting the peptidyl transferase activity of the ribosome, leading to a decrease in LSm3 protein levels. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically binds to the mTOR complex and inhibits its activity, leading to the downregulation of cap-dependent mRNA translation, potentially reducing the synthesis of LSm3. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine incorporates into RNA and DNA and inhibits DNA methyltransferases, possibly causing the reactivation of silenced genes and the subsequent downregulation of LSm3 expression. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid binds to retinoic acid receptors which in turn can bind to retinoic acid response elements in DNA, potentially leading to the decreased transcription of the LSm3 gene. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A binds guanine-cytosine-rich sequences in DNA, inhibiting RNA polymerase and possibly leading to a decrease in LSm3 mRNA synthesis. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2′-Deoxycytidine is incorporated into DNA where it inhibits DNA methyltransferases, potentially resulting in hypomethylation of the LSm3 gene promoter and a reduction in gene expression. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib selectively inhibits CDK4/6, halting cell cycle progression, which could lead to a reduced transcription of genes including LSm3 during the G1 phase. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 competitively binds to BET bromodomains, potentially decreasing the recruitment of transcriptional machinery to the LSm3 gene promoter and diminishing LSm3 transcription. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG 108 directly inhibits DNA methyltransferases, which may lead to a genome-wide demethylation and specific reduction in the transcriptional repression of the LSm3 gene. | ||||||